Victory Capital Management
PHAT icon

Victory Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Victory Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,089
Closed -$54K – 3059
2020
Q1 		$54K Buy
+2,089
New +$69.8K ﹤0.01% 2503

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Victory Capital Management's PHAT Position: Q2 2020 in Review

Victory Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q2 2020, closing a stake of 2,089 shares — an estimated $54K sold.

Victory Capital Management first reported a position in PHAT in Q1 2020 and held it in 1 quarter. The position peaked at $54K in Q1 2020. 61 funds tracked by Wall St. Rank hold PHAT as of Q2 2020.

  • Victory Capital Management reported no remaining Phathom Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 2,089 Phathom Pharmaceuticals shares in Q2 2020, an estimated $54K.
  • Victory Capital Management first reported a position in Phathom Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Victory Capital Management's Phathom Pharmaceuticals position peaked at $54K in Q1 2020.
  • 61 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.